Tiziana Life Sciences (NASDAQ: TLSA) has announced a significant publication in Nature Reviews Neurology regarding its lead candidate, intranasal foralumab. The article discusses foralumab's potential in treating neurodegenerative diseases such as Multiple Sclerosis, Alzheimer's, ALS, and Parkinson's. This highlights the immune system's critical role in these conditions, potentially boosting investor interest in TLSA.